Yilu Zhang

Associate

yilu-zhang
  • JD, New York University School of Law, 2017
  • BA (History), magna cum laude, University of Pennsylvania, 2012
  • BS (Economics), magna cum laude, University of Pennsylvania, 2012

Qualifications

  • Massachusetts, 2017
  • New York, 2021

Yilu Zhang

Associate

Yilu’s practice focuses on intellectual property transactions in the technology and life sciences spaces. She advises public and private technology, biotechnology and pharmaceutical companies, and their investors, in a range of strategic transactions, including licensing and collaboration agreements, supply and distribution arrangements, research-related agreements, mergers and acquisitions, and other commercial agreements and general intellectual property matters. Yilu also counsels clients on data security and privacy issues.

Prior to joining Ropes & Gray, Yilu received the Ann Petluck Poses Memorial Prize for her work as a student attorney in NYU Law’s Technology, Law, and Policy Clinic. She previously worked as a paralegal in the Health Care Fraud unit of the U.S. Attorney’s Office for the District of Massachusetts.

Experience

  • Advised a biotechnology company in a global agreement worth over $1.5 billion to develop and commercialize treatments for mood and movement disorders.
  • Represented Takeda Pharmaceutical Company Limited in renewing collaboration agreements with the Tri-Institutional Therapeutics Discovery Institute, made up of Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine (TDI) and with Bridge Medicines, a biotech company launched by Takeda, TDI, and other investors. 
  • Represented LogicBio Therapeutics, Inc. in its $70 million initial public offering.
  • Represented a global investment company in monitoring and enforcement of its global trademark portfolio.
  • Advised a global investment firm in developing an organization-wide General Data Protection Regulation (GDPR) compliance program.
  • Represented ImmunoGen Inc. in an exclusive collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co. to develop and commercialize mirvetuximab soravtansine, a treatment for ovarian cancer, in Greater China.
  • Represented Takeda Pharmaceutical Company Limited in a strategic collaboration valued at up to $2 billion with Neurocrine Biosciences, Inc. to develop and commercialize possible psychiatric therapies within Takeda’s early-to-mid-stage portfolio, including an exclusive, worldwide license to Neurocrine for seven psychiatry pipeline programs related to schizophrenia, treatment-resistant depression and anhedonia.

Publications

  • Yilu Zhang, “The Incompatibility of Bitcoin’s ‘Strong’ Decentralization Ideology and Its Growth as a Scalable Currency,” 11 N.Y.U. J. L. & Liberty 1 (2017)
  • Yilu Zhang, “An Analysis of Quill and Federal Remote Sales Tax Legislation,” State Tax Notes (July 4, 2016) 

Presentations

  • Presenter, “GDPR for IP (and Other) Lawyers,” Boston Bar Association (April 24, 2019)
  • JD, New York University School of Law, 2017
  • BA (History), magna cum laude, University of Pennsylvania, 2012
  • BS (Economics), magna cum laude, University of Pennsylvania, 2012
Cookie Settings